Update: dealREPORTER Says Biogen Unlikely To Buy Elan

Last week, PropThink reported on Elan’s (NYSE:ELN) potential to fall as a result of bapineuzumab failures and disappearing buy-out speculation. We cited an article from dealREPORTER.com for analysis of Biogen Idec’s (NASDAQ:BIIB) possible acquisition of Elan. At the time of publication, that article was available only to BioPharm Insight subscribers, but it can now be seen at the Financial Times by clicking here.